Downstream Decisions To Maximize Vector Yields And Reduce COGs

Gene therapies are among the most expensive biopharmaceuticals to develop and manufacture, due in large part to persistent bottlenecks in downstream processing. When purification workflows lose 10% to 30% of vector at each unit operation, it forces developers to make critical tradeoffs to maximize yield without compromising product quality.

Join Bioprocess Online on Thursday, May 28, at 11 a.m. Eastern for a live panel discussion with Hung Trinh, Ph.D., CEO at Vertex Biopharm Consulting, and Nathalie Clément, Ph.D., senior VP of vector development at Siren Biotechnology. These experts will explore how teams are finding success overcoming challenges in downstream purification, as well as how factors like vector type, dose, and route of administration can influence downstream design.

They will also address evolving regulatory expectations, including recent FDA and EMA perspectives, and what they mean for process validation, analytics, and commercial readiness.